Compared to other diabetes medications, tirzepatide hits blood sugar and weight loss goals faster, according to new research examining the time it takes to reach blood glucose goals. According to the most recent analyzes of the SURPASS-2 and SURPASS-3 studies, adults treated with different doses of injectable tirzepatide (5, 10 and 15 mg) achieved blood glucose target values approximately four weeks earlier than those treated with injectable semaglutide (1 mg), and between four and 12 weeks earlier than those who received insulin (degludec; iDe) once daily. These findings were presented this year at the annual meeting of the European Association for the Study of Diabetes (EASD) in Stockholm. T2D is a progressive, chronic disease in which the body does not make or use insulin as it should, resulting in elevated blood glucose levels. While there are many medications available to treat diabetes, only about half of U.S. individuals with T2D achieve target hemoglobin A1c (HbA1c; a measure of blood sugar management) below 7%. This is despite the fact that more than 30 million Americans have T2D. Higher HbA1c levels have been linked to problems such as heart disease, stroke, nephropathy, retinopathy, and nerve disorders in the kidneys and eyes (neuropathy).